Infection incidence, timing, and predictors in newly diagnosed multiple myeloma: a real-world retrospective cohort study - Scorecard - MDSpire

Infection incidence, timing, and predictors in newly diagnosed multiple myeloma: a real-world retrospective cohort study

  • By

  • Ozlem Candan

  • Narmin Naghizada

  • Tekin Tuncel

  • Beyza Melek Palaz

  • Mustafa Alperen Tunc

  • Derya Demirtas

  • Ahmet Mert Yanik

  • Arda Bayar

  • Secil Salim

  • Fatma Temiz

  • Ceren Uzunoglu Guren

  • Fatma Arıkan

  • Meral Ulukoylu Menguc

  • Asu Fergun Yilmaz

  • Isik Atagunduz

  • Zekaver Odabası

  • Tayfur Toptas

  • Ayse Tulin Tuglular

  • May 14, 2026

  • 0 min

Share

Clinical Scorecard: Infection Rates, Timing, and Predictive Factors in Recently Diagnosed Multiple Myeloma: A Retrospective Cohort Analysis

At a Glance

CategoryDetail
ConditionMultiple Myeloma (MM)
Key MechanismsImmune suppression due to disease and treatment, hypogammaglobulinemia, myelosuppression, and comorbidities.
Target PopulationPatients newly diagnosed with multiple myeloma undergoing standard induction treatment.
Care SettingTertiary care facility

Key Highlights

  • Infections occurred in 50.9% of patients, peaking in the first 3 months.
  • Pneumonia was the most common infection (34.1%).
  • Advanced ISS stage, diabetes, and chronic kidney disease are significant risk factors for infection.
  • Gram-negative organisms, particularly E. coli, Klebsiella spp., and Pseudomonas aeruginosa, were prevalent.
  • Lymphocyte levels decreased during febrile episodes.

Guideline-Based Recommendations

Diagnosis

  • Monitor clinical and laboratory data for infection risk factors.

Management

  • Implement risk-adjusted infection prevention strategies based on clinical indicators.

Monitoring & Follow-up

  • Regularly assess for infections, particularly in the first 6 months of treatment.

Risks

  • Increased risk of infections due to immune suppression and comorbidities.

Patient & Prescribing Data

Newly diagnosed multiple myeloma patients aged 18 and older.

Standard induction protocols include bortezomib-based and lenalidomide-based regimens.

Clinical Best Practices

  • Utilize prophylactic antibiotics judiciously to mitigate infection risks.
  • Tailor infection prevention strategies to individual patient risk profiles.

Related Resources & Content

Original Source(s)

Related Content